Purpose of this Study
We are doing this study to test different drugs to see if they are safe and helpful for adults who are admitted in the hospital with acute respiratory distress syndrome (ARDS) compared to placebo (a substance that looks like a drug but does not contain an active drug).
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are admitted to the hospital with a diagnosis of ARDS
- Are not pregnant or nursing
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is called a platform study. A platform study is a study where several drugs are tested at the same time to figure out which drugs are most effective at helping resolve symptoms and restore people's health.
If you choose to join the study, you will get a random assignment to be treated with one of the following 4 options:
- vilobelimab; OR
- paridiprubart; OR
- bevacizumab (Avastin®); OR
- placebo
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
Phase 2 Clinical Platform Trial Investigating Multiple Therapeutic Options for the Treatment of Hospitalized Patients with Acute Respiratory Distress Syndrome (ARDS) BP-ARDS-P2-001_(Advarra IRB)
Principal Investigator
Christina
Barkauskas
Protocol Number
PRO00118116
NCT ID
NCT06703073
Phase
II
Enrollment Status
Pending Open to Enrollment